TopFunds

Idexx Laboratories

NASDAQ: IDXX

Stock price

513.14 USD

(+0%) TODAY

Health Care EquipmentMedical - Diagnostics & ResearchInvestable Universe
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
2.1
2.4
2.9
4.3
4.9
6.7
8.6
8
10.1
10.7
13.1
20.4%
02Free cash flow per share
1.4
3
3.3
3.1
3.5
6.2
7.3
4.7
9.2
9.6
13.1
24.8%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
1,602
1,775
1,969
2,213
2,407
2,707
3,215
3,367
3,661
3,898
4,304
10.4%
06% Change
-
-
-
-
-
-
-
-
-
-
-
10.4%
07Cost of revenue
(711.6)
(800)
(871.7)
(971.7)
(1,041)
(1,136)
(1,326)
(1,363)
(1,471)
(1,519)
(1,644)
8.7%
08Gross profit
890.3
975.4
1,097
1,242
1,366
1,571
1,889
2,004
2,190
2,379
2,660
11.6%
09% Margin
55.6%
54.9%
55.7%
56.1%
56.7%
58%
58.8%
59.5%
59.8%
61%
61.8%
58% A
10Operating expenses
(582.1)
(625.2)
(684.4)
(750.2)
(812.7)
(876.5)
(957.4)
(1,106)
(1,093)
(1,251)
(1,300)
8.4%
11% of Revenue
(36.3)%
(35.2)%
(34.8)%
(33.9)%
(33.8)%
(32.4)%
(29.8)%
(32.8)%
(29.9)%
(32.1)%
(30.2)%
(32.8)% A
12Operating Income
299.9
350.2
413
491.3
552.8
694.5
932
898.8
1,097
1,128
1,360
16.3%
13Income tax expense
(81)
(99.8)
(117.8)
(80.7)
(94.4)
(79.9)
(157.8)
(180.9)
(216.1)
(222)
(264.7)
12.6%
14Net Income
192.1
222
263.1
377
427.7
581.8
744.8
679.1
845
887.9
1,060
18.6%
15% Margin
12%
12.5%
13.4%
17%
17.8%
21.5%
23.2%
20.2%
23.1%
22.8%
24.6%
18.9% A
16Shares Outstanding
93.6
90.9
89.6
88.5
87.5
86.7
86.6
84.6
84
83.2
80.7
(1.5)%
17EPS Basic
2.1
2.5
3
4.3
5
6.8
8.7
8.1
10.2
10.8
13.2
20.3%
18EPS Diluted
2.1
2.4
2.9
4.3
4.9
6.7
8.6
8
10.1
10.7
13.1
20.4%
19EBITDA
370.3
431.7
501.4
575.7
643.7
793.8
1,040
1,015
1,218
1,276
1,469
14.8%
% Margin
23.1%
24.3%
25.5%
26%
26.7%
29.3%
32.3%
30.1%
33.3%
32.7%
34.1%
28.9% A
20Net Interest Income (expense)
(26.8)
(28.4)
(32)
(33.6)
(30.6)
(32.5)
(29.4)
(38.8)
(36)
(18.5)
(35.8)
3%
21Net Debt / EBITDA
2.8
2.4
2.1
1.5
1.5
0.8
0.9
1.3
0.5
0.5
0.6
1.4 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
129
154.9
187.7
123.8
90.3
383.9
144.5
112.5
453.9
288.3
180.1
3.4%
23Short-term investments
213.6
236.9
284.3
-
-
-
-
-
-
-
-
15.4%
24Accounts receivable
200.1
232.2
270.1
258.5
307.5
374.7
425.6
490.9
529.5
561.3
693.2
13.2%
25Other current assets
129.1
117
130.1
84.5
86.8
94.2
116.6
130.2
131.5
168.4
89.2
(3.6)%
26Inventory
188.8
158
164.3
173.3
195
209.9
269
367.8
380.3
381.9
377.8
7.2%
27Total Current Assets
821.6
845.6
972
654.2
679.6
1,063
955.7
1,102
1,495
1,400
1,340
5%
Non-Current Assets
28Net property, plant & equipment
333
357.4
379.1
437.3
614.5
646.3
692.8
768.1
817.7
829.3
870.6
10.1%
29Long-term investments
12.2
11
9.9
10.9
13.7
12.1
18.6
55.5
56.2
57.7
297.1
37.7%
30Other non-current assets
308.2
316.7
352.4
435
524.7
573.4
770.2
821.7
890.8
1,007
842.8
10.6%
31Total Non-Current Assets
653.4
685.1
741.4
883.2
1,153
1,232
1,482
1,645
1,765
1,894
2,011
11.9%
Total Assets
1,475
1,531
1,713
1,537
1,833
2,295
2,437
2,747
3,260
3,293
3,351
8.6%
LIABILITIES
Current Liabilities
32Accounts payable
52.6
60.1
67
69.5
72.2
74.6
116.1
110.2
110.6
114.2
110.4
7.7%
33Short-term debt
573
611
655
398.9
304
67.7
168.4
674.4
344.8
439.3
500.1
(1.4)%
34Other current liabilities
231.1
263.5
282.6
302
349.1
440.5
479
451.2
496.1
514.4
538.3
8.8%
35Total Current Liabilities
856.8
934.6
1,005
770.4
725.3
582.8
763.6
1,236
951.5
1,068
1,149
3%
Non-Current Liabilities
36Long-term debt
597.1
593.1
606.1
601.3
766.4
935.5
862.6
795.6
722.6
547.6
577.1
(0.3)%
37Other non-current liabilities
105.1
111.2
156.6
174.8
162.9
143.5
121.1
106.6
101.3
82.6
19.4
(15.5)%
38Total Non-Current Liabilities
702.2
704.3
762.7
776.1
929.3
1,079
983.6
902.2
823.8
630.2
596.6
(1.6)%
39Total Liabilities
1,559
1,639
1,767
1,547
1,655
1,662
1,747
2,138
1,775
1,698
1,745
1.1%
SHAREHOLDERS` EQUITY
40Common stock
10.3
10.3
10.4
10.5
10.6
10.6
10.7
10.7
10.8
10.8
10.8
0.6%
41Retained earnings / (deficit)
318.4
540.4
803.5
1,168
1,596
2,176
2,920
3,600
4,445
5,332
6,392
35%
42Accumulated other comprehensive income / (loss)
(42.3)
(43.1)
(36.5)
(41.8)
(46.2)
(53.6)
(53.5)
(77.8)
(71.2)
(93.6)
(68.8)
5%
43Noncontrolling interests
0.1
0.1
0.3
0.3
0.4
0.7
-
-
-
-
-
40.3%
44Total shareholders' equity
(84)
(108.2)
(53.8)
(9.2)
177.8
632.8
690
608.7
1,485
1,595
1,605
-
45Total Liabilities and shareholders' Equity
1,475
1,531
1,713
1,537
1,833
2,295
2,437
2,747
3,260
3,293
3,351
8.6%
46Total Debt
1,170
1,204
1,261
1,000
1,070
1,003
1,031
1,470
1,067
986.9
1,077
(0.8)%
47Net Debt
1,041
1,049
1,073
876.5
980.1
619.3
886.6
1,358
613.4
698.7
897.1
(1.5)%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
192.1
222
263.1
377
427.7
581.8
744.8
679.1
845
887.9
1,060
18.6%
49Depreciation & amortization
69
78.2
83.1
83.2
88
96
104.6
111.9
114.9
129.9
145.2
7.7%
50Share-based compensation expense
19.9
19.9
23.5
25.2
39.3
31
37.8
49.8
59.7
60.3
-
13.1%
51Changes in working capital and other assets
(64.6)
14.4
3.5
(85.3)
(95.9)
(60.7)
(131.6)
(297.8)
(113.2)
(149.1)
(26.6)
(8.5)%
52Net cash flows from operating activities
216.4
334.6
373.3
400.1
459.2
648.1
755.5
543
906.5
929
1,178
18.5%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(82.9)
(64.8)
(76.7)
(122.9)
(155.2)
(107.6)
(119.5)
(148.8)
(133.6)
(120.9)
(138.2)
5.2%
54Purchases of investments / marketable securities
(272)
(227.9)
(334.2)
(0.1)
-
-
-
(25)
-
-
(0.8)
(44.5)%
55Proceeds from maturities of marketable securities
56.8
203.9
286.8
284.1
-
-
-
71.5
-
1.6
-
(32.9)%
56Other investing activities
(10.3)
(2)
(14.6)
(22.5)
(50.3)
(1.7)
(173.4)
(93)
8.4
(87.7)
2.7
-
57Net cash flows from investing activities
(308.4)
(90.8)
(138.7)
138.6
(205.5)
(109.4)
(293)
(195.3)
(125.3)
(207.1)
(136.2)
(7.9)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(379.6)
(265.7)
(252)
(331.1)
(265.6)
(131.5)
(700.2)
(784)
(24.9)
(792.5)
(1,124)
11.5%
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
272.7
38
44
(256)
(10.3)
(94.6)
23.5
430.5
(404)
(75)
(30.4)
-
61Other financing activities
11.3
9.9
-
(10.6)
(10.6)
(22.3)
(20.7)
(17.5)
(13.1)
(10.5)
(7.2)
-
62Net cash flows from financing activities
(95.6)
(217.8)
(208)
(597.8)
(286.4)
(248.4)
(697.4)
(370.9)
(442)
(878.1)
(1,161)
28.4%
63Increase (decrease) in cash and cash equivalents
(193.5)
25.9
32.8
(63.9)
(33.5)
293.6
(239.5)
(31.9)
341.4
(165.7)
(108.2)
(5.7)%
64Cash and equivalents, ending balance
129
154.9
187.7
123.8
90.3
383.9
144.5
112.5
453.9
288.3
180.1
3.4%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
133.4
269.8
296.6
277.1
303.9
540.4
636
394.1
772.9
808.1
1,040
22.8%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Idexx Laboratories (IDXX) financial statements and performance

Explore Idexx Laboratories (IDXX) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.